In contrast to the expression of somatostatin receptors, which are limited to neuroendocrine tumors, the substantial potential of bombesin as a drug vehicle largely benefits from the overexpression or ectopical expression of bombesin receptors, especially GRPR, in a wide range of lethal malignancies [8], [12], [33]. The gene discussed is GRPR; the disease is neuroendocrine neoplasm.